EIF4E and melanoma: In a recent study, high‐throughput drug screening identified SBI‐0640756 as a new first‐in‐class inhibitor that targets EIF4G1 through disrupting the EIF4F complex and attenuates the growth of clinically unresponsive melanomas.30